EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer
Por:
Serrano, MJ, Ortega, FG, Alvarez-Cubero, MJ, Nadal, R, Sanchez-Rovira, P, Salido, M, Rodriguez, M, Garciia-Puche, JL, Delgado-Rodriguez, M, Francesc Solé, Garcia, MA, Peran, M, Rosell, R, Marchal, JA and Lorente, JA
Publicada:
15 sep 2014
Categoría:
Oncology
Resumen:
Circulating tumor cells (CTCs) are frequently associated with epithelial-mesenchymal transition (EMT). The objective of this study was to detect EMT phenotype through Vimentin (VIM) and Slug expression in cytokeratin (CK)-negative CTCs in non-metastatic breast cancer patients and to determine the importance of EGFR in the EMT phenomenon. In CK-negative CTCs samples, both VIM and Slug markers were co-expressed in the most of patients. Among patients EGFR+, half of them were positive for these EMT markers. Furthermore, after a systemic treatment 68% of patients switched from CK- to CK+ CTCs. In our experimental model we found that activation of EGFR signaling by its ligand on MCF-7 cells is sufficient to increase EMT phenotypes, to inhibit apoptotic events and to induce the loss of CK expression. The simultaneous detection of both EGFR and EMT markers in CTCs may improve prognostic or predictive information in patients with operable breast cancer.
Filiaciones:
Serrano, MJ:
Univ Granada, Andalusian Govt Ctr Genom & Oncol, GENYO Pfizer, Granada, Spain
Univ Granada, Dept Legal Med, Lab Genet Identificat UGR, Granada, Spain
Ortega, FG:
Univ Granada, Andalusian Govt Ctr Genom & Oncol, GENYO Pfizer, Granada, Spain
Alvarez-Cubero, MJ:
Univ Granada, Andalusian Govt Ctr Genom & Oncol, GENYO Pfizer, Granada, Spain
Univ Granada, Dept Legal Med, Lab Genet Identificat UGR, Granada, Spain
Nadal, R:
Hosp Barcelona, Dept Med Oncol, Barcelona, Spain
Sanchez-Rovira, P:
Univ Jaen, CIBERESP, Div Prevent Med & Publ Hlth, Jaen, Spain
Salido, M:
Hosp del Mar, Mol Cytogenet Lab, Dept Pathol, IMIM,GRETNHE, Barcelona, Spain
Rodriguez, M:
Univ Jaen, CIBERESP, Div Prevent Med & Publ Hlth, Jaen, Spain
Hosp del Mar, Mol Cytogenet Lab, Dept Pathol, IMIM,GRETNHE, Barcelona, Spain
Garciia-Puche, JL:
Univ Granada, Andalusian Govt Ctr Genom & Oncol, GENYO Pfizer, Granada, Spain
Delgado-Rodriguez, M:
Univ Jaen, CIBERESP, Div Prevent Med & Publ Hlth, Jaen, Spain
Francesc Solé:
Univ Autonoma Barcelona, Dept Med, E-08193 Barcelona, Spain
Inst Recerca Leucemia Josep Carreras, Badalona, Spain
Garcia, MA:
Univ Hosp, Dept Oncol, Granada, Spain
Peran, M:
Univ Jaen, CIBERESP, Div Prevent Med & Publ Hlth, Jaen, Spain
Univ Granada, Ctr Biomed Res, Biopathol & Regenerat Med Inst IBIMER, Granada, Spain
:
Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain
USP Dexeus Univ Inst, Pangaea Biotech SL, Barcelona, Spain
Marchal, JA:
Univ Granada, Ctr Biomed Res, Biopathol & Regenerat Med Inst IBIMER, Granada, Spain
Univ Granada, Dept Human Anat & Embryol, Granada, Spain
Lorente, JA:
Univ Granada, Andalusian Govt Ctr Genom & Oncol, GENYO Pfizer, Granada, Spain
Univ Granada, Dept Legal Med, Lab Genet Identificat UGR, Granada, Spain
gold, Green Submitted, Green Published
|